Why Boston Scientific (BSX) shares are plunging today
Boston Scientific (BSX) shares fell 8% after reporting Q3 2026 net sales growth of 1.5% to $5.138B and adjusted EPS of $0.73, in line with estimates. The company cited ongoing efforts to restore operations following a cybersecurity incident. The stock is down 55.7% YTD and 60.1% from its 52-week high.
How this was made
The 30-second read
Why it matters
The earnings miss on sales growth and the cyber‑security event combined to drive an 8% intraday decline, creating a possible buying opportunity for risk‑tolerant traders.
Market read
The first‑time earnings release with a notable price move makes this article highly relevant for traders focused on healthcare equities.
What to watch
Potential cost‑saving measures post‑incident and the fact that earnings per share beat estimates by a small margin.
Background
Boston Scientific disclosed Q3 2026 financial results and a recent cybersecurity incident that disrupted operations.
Ticker impact
Boston Scientific shares fell 8% in the morning after the company released Q3 2026 results showing only 1.5% sales growth and disclosed a cybersecurity incident.
likely continued pressure as investors price in weaker near‑term outlook and operational risks
The earnings release is the first report of the numbers, the stock moved >5% on the same day, and the guidance fell short of expectations, all of which are strong bearish catalysts.
Market effects
Medical‑device sector may see heightened scrutiny on cyber‑risk management, potentially affecting peers.
U.S. healthcare stocks could face broader sell pressure in the near term.
Limited to U.S. markets; no immediate global macro effect.
Counterpoint
The 8% dip may be an overreaction; the company still posted GAAP profit and could rebound if cyber issues are resolved quickly.
Key entities
- CompanyBoston Scientific
Medical‑device maker reporting Q3 2026 results.
- ExecutiveMike Mahoney
Chairman and CEO of Boston Scientific who commented on the cyber incident.
